Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilma D Heemsbergen

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
International Journal of Radiation Oncology, Biology, Physics|November 6, 2021
Patient-Reported Outcomes in the Acute Phase of the Randomized Hypofractionated Irradiation for Prostate Cancer (HYPRO) TrialFelix Sinzabakira, Wilma D Heemsbergen, Floris J Pos, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2022
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort studyNoortje Verschoor, Wilma D Heemsbergen, Joost L Boormans, et al.
The Journal of Sexual Medicine|September 26, 2016
Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO TrialRuud C Wortel, Floris J Pos, Wilma D Heemsbergen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 16, 2010
Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trialAbrahim Al-Mamgani, Wilma D Heemsbergen, Peter C Levendag, et al.
Acta Oncologica (Stockholm, Sweden)|November 20, 2018
Prediction of early mortality following stereotactic body radiotherapy for peripheral early-stage lung cancerSarah Baker, Aman Sharma, Robert Peric, et al.
Translational Andrology and Urology|August 5, 2024
Risk factors for secondary bladder cancer following prostate cancer radiotherapyMarie-Christina Jahreiß, Wilma D Heemsbergen, Katja K H Aben, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2008
Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancerAbrahim Al-Mamgani, Wilma D Heemsbergen, Stephanie T H Peeters, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Radiobiological Modeling for Acute Proctitis After Conventional and Hypofractionated Radiation Therapy for Prostate CancerChristian A M Jongen, Ben J M Heijmen, Luca Incrocci, et al.
International Journal of Radiation Oncology, Biology, Physics|November 21, 2018
Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO TrialRuud C Wortel, Esther Oomen-de Hoop, Wilma D Heemsbergen, et al.
Cancers|January 8, 2025
Added Value of Biological Effective Dose in Dosiomics-Based Modelling of Late Rectal Bleeding in Prostate CancerChristian A M Jongen, Wilma D Heemsbergen, Luca Incrocci, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
International Journal of Radiation Oncology, Biology, Physics|November 6, 2021
Patient-Reported Outcomes in the Acute Phase of the Randomized Hypofractionated Irradiation for Prostate Cancer (HYPRO) TrialFelix Sinzabakira, Wilma D Heemsbergen, Floris J Pos, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2022
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort studyNoortje Verschoor, Wilma D Heemsbergen, Joost L Boormans, et al.
The Journal of Sexual Medicine|September 26, 2016
Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO TrialRuud C Wortel, Floris J Pos, Wilma D Heemsbergen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 16, 2010
Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trialAbrahim Al-Mamgani, Wilma D Heemsbergen, Peter C Levendag, et al.
Acta Oncologica (Stockholm, Sweden)|November 20, 2018
Prediction of early mortality following stereotactic body radiotherapy for peripheral early-stage lung cancerSarah Baker, Aman Sharma, Robert Peric, et al.
Translational Andrology and Urology|August 5, 2024
Risk factors for secondary bladder cancer following prostate cancer radiotherapyMarie-Christina Jahreiß, Wilma D Heemsbergen, Katja K H Aben, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2008
Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancerAbrahim Al-Mamgani, Wilma D Heemsbergen, Stephanie T H Peeters, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Radiobiological Modeling for Acute Proctitis After Conventional and Hypofractionated Radiation Therapy for Prostate CancerChristian A M Jongen, Ben J M Heijmen, Luca Incrocci, et al.
International Journal of Radiation Oncology, Biology, Physics|November 21, 2018
Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO TrialRuud C Wortel, Esther Oomen-de Hoop, Wilma D Heemsbergen, et al.
Cancers|January 8, 2025
Added Value of Biological Effective Dose in Dosiomics-Based Modelling of Late Rectal Bleeding in Prostate CancerChristian A M Jongen, Wilma D Heemsbergen, Luca Incrocci, et al.
Pageof 8